Literature DB >> 12780754

Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth.

Y Greenman1, G Ouaknine, I Veshchev, I I Reider-Groswasser, Y Segev, N Stern.   

Abstract

BACKGROUND: Postoperative management of clinically nonfunctioning pituitary adenomas (NFPA) presents difficult challenges. There are no good serum markers for presence or growth of the tumour, medical treatment is not effective and radiotherapy carries the risk of significant side-effects.
OBJECTIVE: The purpose of this study was to investigate the natural history and biological behaviour of surgically treated NFPA, with a special effort to identify characteristics indicative of a more aggressive course that could assist in the clinical decision-making process. STUDY
DESIGN: Patients operated on at our institution for NFPA undergo uniform routine clinical follow-up at the endocrine clinic. Magnetic resonance imaging (MRI) studies are performed 3, 6 and 12 months after transsphenoidal surgery and yearly thereafter for the first 5 years. Subsequently, imaging is performed once every 2 years or as clinically indicated. From 1992 onwards, no patient received immediate postoperative radiation therapy. PATIENTS: One hundred and twenty-two patients (78M/45F) operated on at our institution since 1989 and with a minimal follow-up of 1 year comprised the study group. MEASUREMENTS: Tumour size and characteristics were determined by MRI using a modification of Hardy's and Wilson's classifications. Maximal tumour height was also recorded and the information was routinely stored in a computerized database.
RESULTS: Mean (+/- SD) follow-up was 51 +/- 31 months. Fourteen patients received postoperative radiation therapy. Subsequent tumour growth was observed in five of them, reduction in tumour size in four and no size changes in five. One hundred and eight patients did not receive postoperative radiation. Tumour enlargement occurred in 41 of 78 and in six of 30 patients with and without residual tumour after operation (P = 0.0024). The presence of cavernous sinus invasion before surgery [P = 0.02, odds ratio (OR) 2.72; confidence interval (CI) 1.1-6.43] and the extent of suprasellar extension in the postoperative tumour remnant (P = 0.0054 for presence of stage A, OR 4.4; 95% CI 1.5-12.5; and P = 0.012 for presence of stages B or C, OR 16.2; CI 1.8-144) were strong independent predictors of tumour enlargement.
CONCLUSION: Our data may ease the selection of patients in whom radiation therapy is likely to be necessary for tumour control, and confirms that close postoperative follow-up is an adequate primary approach in low-risk patients.

Entities:  

Mesh:

Year:  2003        PMID: 12780754     DOI: 10.1046/j.1365-2265.2003.01784.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  52 in total

Review 1.  Radiotherapy for non-functioning pituitary tumors--when and under what circumstances?

Authors:  Neil J L Gittoes
Journal:  Pituitary       Date:  2003-09       Impact factor: 4.107

2.  Determinants of neurosurgical outcome in pituitary tumors.

Authors:  M J Barahona; L Sojo; A M Wägner; F Bartumeus; B Oliver; P Cano; S M Webb
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

Review 3.  Optimal management of non-functioning pituitary adenomas.

Authors:  Yona Greenman; Naftali Stern
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

4.  Fractionated stereotactic radiotherapy in the treatment of pituitary adenomas.

Authors:  C Kopp; M Theodorou; N Poullos; S T Astner; H Geinitz; G K Stalla; B Meyer; M Molls; C Nieder; A-L Grosu
Journal:  Strahlenther Onkol       Date:  2013-09-08       Impact factor: 3.621

5.  Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas.

Authors:  Erica C Garcia; Luciana A Naves; Arthur O Silva; Lucas F de Castro; Luiz A Casulari; Monalisa F Azevedo
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

Review 6.  Central hypothyroidism and its role for cardiovascular risk factors in hypopituitary patients.

Authors:  Ulla Feldt-Rasmussen; Marianne Klose
Journal:  Endocrine       Date:  2016-08-01       Impact factor: 3.633

7.  Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study.

Authors:  Alessandra Fusco; Antonella Giampietro; Antonio Bianchi; Vincenzo Cimino; Francesca Lugli; Serena Piacentini; Margherita Lorusso; Anna Tofani; Germano Perotti; Libero Lauriola; Carmelo Anile; Giulio Maira; Alfredo Pontecorvi; Laura De Marinis
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

8.  Volumetric measurement for comparison of the accuracy between intraoperative CT and postoperative MR imaging in pituitary adenoma surgery.

Authors:  C-C Lee; S-T Lee; C-N Chang; P-C Pai; Y-L Chen; T-C Hsieh; C-C Chuang
Journal:  AJNR Am J Neuroradiol       Date:  2011-06-23       Impact factor: 3.825

9.  A single-institution restrospective experience of brachytherapy in the treatment of pituitary tumors: transsphenoidal approach combined with (192)Ir-afterloading catheters.

Authors:  A Di Mambro; C Giuliani; F Ammannati; E Mannucci; S Scoccianti; B Detti; I Meattini; P Mennonna; G Forti; M Serio; A Peri
Journal:  J Endocrinol Invest       Date:  2009-12-01       Impact factor: 4.256

Review 10.  Radiotherapy of nonfunctioning and gonadotroph adenomas.

Authors:  Andrew A Kanner; Benjamin W Corn; Yona Greenman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.